Maat Pharma SA - Asset Resilience Ratio

Latest as of June 2025: 0.06%

Maat Pharma SA (MAAT) has an Asset Resilience Ratio of 0.06% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€31.00K

≈ $36.24K USD Cash + Short-term Investments

Total Assets

€48.88 Million

≈ $57.14 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2024)

This chart shows how Maat Pharma SA's Asset Resilience Ratio has changed over time. Check MAAT PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Maat Pharma SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MAAT market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€31.00K	0.06%
Total Liquid Assets	€31.00K	0.06%

Asset Resilience Insights

Limited Liquidity: Maat Pharma SA maintains only 0.06% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Maat Pharma SA Industry Peers by Asset Resilience Ratio

Compare Maat Pharma SA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Sk Biopharmaceuticals Co Ltd KO:326030	Biotechnology	0.14%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Hangzhou Biotest Biotech Co Ltd SHG:688767	Biotechnology	0.56%
Theravance Biopharma Inc F:0TB	Biotechnology	37.29%

Annual Asset Resilience Ratio for Maat Pharma SA (2022–2024)

The table below shows the annual Asset Resilience Ratio data for Maat Pharma SA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	22.75%	€8.76 Million ≈ $10.24 Million	€38.50 Million ≈ $45.01 Million	-22.54pp
2023-12-31	45.29%	€19.44 Million ≈ $22.73 Million	€42.93 Million ≈ $50.19 Million	+3.69pp
2022-12-31	41.60%	€18.61 Million ≈ $21.75 Million	€44.73 Million ≈ $52.29 Million	--

pp = percentage points

About Maat Pharma SA

PA:MAAT France Biotechnology

Market Cap

$61.16 Million

€52.32 Million EUR

Market Cap Rank

#21104 Global

#331 in France

Share Price

€2.79

Change (1 day)

+0.00%

52-Week Range

€2.36 - €7.78

All Time High

€13.95